Longevity
The science of living longer
Description
A baby born in the United States in 1900 could expect to live about forty-seven years. A baby born in 2020 can expect to live about seventy-seven years. The thirty-year increase is the largest single expansion of life expectancy in human history, and most of it happened in the first half of the twentieth century — driven by public health measures, vaccines, antibiotics, and improved nutrition that reduced infant mortality and eliminated many infectious diseases as causes of early death. The second half of the twentieth century and the early twenty-first have added comparatively modest years, mostly through reduced cardiovascular mortality. The trajectory of gains has been slowing, not accelerating, despite enormous investment in biomedical research.
Against this backdrop, a specific movement has emerged in the past decade claiming that aging itself can be slowed, halted, or possibly reversed. Silicon Valley billionaires fund longevity research at unprecedented scales — Calico (Google), Altos Labs (Jeff Bezos, Yuri Milner), the Hevolution Foundation (Saudi Arabia). Celebrity doctors like Peter Attia and David Sinclair publish bestsellers and host podcasts with audiences in the millions. Specific protocols proliferate — rapamycin, metformin, NAD+ precursors, senolytics, intermittent fasting, caloric restriction. The claims range from modest (compress morbidity, add a few healthy years) to radical (escape velocity, the first person to live to 150 is alive today). Sorting what's supported from what's hype is one of the harder exercises in contemporary science reading.
What the evidence actually shows is more interesting than either the boosters or the skeptics present. Aging has biological mechanisms that are increasingly well understood. Some interventions have produced substantial lifespan extensions in model organisms. Translation to humans is harder than in mice, and the timescales required to test interventions in human longevity are substantial. Meanwhile, a small set of boring but well-established behaviors — not smoking, moving enough, not being overweight, maintaining social connections, getting enough sleep — produce lifespan effects that any pharmaceutical intervention would be celebrated for. Understanding what actually moves the needle, and what is noise, is the specific challenge the field faces.
● The question we're asking: what does longevity science actually show, and what should someone hoping to live longer actually do?
● What we'll see: the historical gains, the biology of aging, the current interventions, and the practical trade-offs.
Table of contents
01The historical gains
The dramatic expansion of life expectancy over the twentieth century was not produced by medicine in any conventional sense. The largest contributions came from public health — sanitation, clean water, immunization, improved nutrition, reduced childhood mortality. A child who survived to age five in 1900 had a reasonable chance of reaching sixty, which is not very different from the current picture once infant mortality is accounted for. What changed dramatically was the chance of making it through early childhood and early adulthood without dying from infectious disease. Penicillin and broader antibiotic use from the 1940s onward extended the gains by making previously fatal bacterial infections survivable.
The second wave of gains, roughly from 1950 to 2000, came from reductions in cardiovascular mortality. The combined effect of declining smoking rates, statins, improved hypertension management, and acute cardiac care roughly halved the age-adjusted death rate from heart disease and stroke. The gains added perhaps five to ten years to life expectancy for adults. Cancer mortality has also declined modestly, though the contribution to overall life expectancy has been smaller than cardiovascular gains because cancer deaths are more distributed across ages rather than concentrated in middle age where they would have the biggest life-expectancy impact.
02The biology of aging
The scientific understanding of aging has advanced substantially over the past several decades. Aging is not a single process but a convergence of multiple mechanisms — the 2013 paper 'The Hallmarks of Aging' identified nine (later expanded to twelve) specific cellular and molecular processes that together produce the deterioration we call aging. These include genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. Each hallmark is a potential intervention target, and research on all of them has accelerated in the past decade.
Cellular senescence is particularly interesting. Senescent cells are cells that have stopped dividing but have not died; they accumulate with age and secrete inflammatory signals that damage surrounding tissue. Drugs that selectively kill senescent cells — senolytics — have produced dramatic lifespan extensions in mice and modest evidence of benefit in early human trials. Whether the approach will produce the hoped-for lifespan effects in humans remains to be seen, but senolytics are among the most promising specific interventions currently in development.
03The current interventions
Rapamycin has accumulated the strongest evidence of any specific pharmacological longevity intervention. Originally developed as an immunosuppressant, it consistently extends lifespan in mice by 10-20% even when started late in life. It acts through the mTOR pathway, a central nutrient-sensing system that also regulates cellular autophagy. Human trials for longevity-specific uses are ongoing. The specific doses being tested are lower and more intermittent than the immunosuppressive doses used in transplant patients, which should reduce the infection and other risks associated with standard rapamycin use. Whether it produces meaningful human longevity effects is not yet determined, but rapamycin is the current front-runner.
Metformin, a cheap generic diabetes drug, has produced suggestive evidence for longevity benefits. Diabetic patients taking metformin appear to have longer lifespans than non-diabetic controls in some studies, which is surprising given that diabetics typically have shorter lifespans. The TAME trial (Targeting Aging with Metformin), designed to test whether metformin delays age-related disease in non-diabetic adults, has been stalled by funding and regulatory challenges for years. If it eventually runs, it would be a landmark in longevity research — the first large-scale human trial specifically aimed at slowing aging rather than treating a specific disease.
04The practical trade-offs
The paradox of contemporary longevity research is that the interventions with the strongest evidence are the least glamorous. Not smoking adds roughly ten years to life expectancy. Moderate regular exercise adds another three to five. Maintaining a healthy weight, avoiding excessive alcohol, and getting adequate sleep add further years. Maintaining strong social connections adds perhaps two to three years through reduced cardiovascular and stress-related mortality. These behavioral factors, collectively, produce lifespan effects that no pharmaceutical intervention has come close to replicating. An intervention that produced a three-year lifespan extension through a single pill would be celebrated as revolutionary; the equivalent effect from walking more is treated as obvious.
The Blue Zones — regions with unusually long-lived populations, including Okinawa, Sardinia, Ikaria, Nicoya, and Loma Linda — have been studied extensively for longevity clues. The common features are not pharmaceutical but structural: plant-heavy diets, regular moderate physical activity integrated into daily life, strong social and family connections, a sense of purpose, and low-intensity stress management through religion or similar practices. Dan Buettner's Blue Zones books have popularized these findings. The lesson is that lifestyle arrangements, not interventions, produce the biggest effects.
05Conclusion
Longevity science is a real and rapidly advancing field, and the fundamental insight that aging is a modifiable biological process rather than an immutable fate is increasingly well supported. Specific interventions — rapamycin, senolytics, epigenetic reprogramming — are promising and may eventually produce meaningful human lifespan extensions. The timescales required to validate these interventions in humans are long, and the commercial pressure to oversell unproven interventions is substantial. Separating the real science from the hype requires specific effort and, often, specialist knowledge that most consumers lack.